Address: Changsha National Biomedical Industrial Base, Changsha City, China
Tel: -5790426
We are a old Intermediates manufacturer,specialized in Sumatriptan,Zomitriptan,Eletriptan,Rosuvastatin Intermediates.Hold about 60~80% of triptan market in China.
We are a old Intermediates manufacturer,specialized in Sumatriptan,Zomitriptan,Eletriptan,Rosuvastatin Intermediates.Hold about 60~80% of triptan market in China.
The latest news from Chinese pharma, including a new report showing that despite the increasing number of Priority Review and Breakthrough Therapy designations awarded within China, only two Accelerated Approval…
The latest news from Chinese pharma and biotech, including BMS’ attempts to pull out of its Abraxane supply deal with local player BeiGene; a conversation with Qihan Biotech CEO Luhan…
The following is an overview from Accestra Consulting* of Part 2 of China’s Center for Drug Evaluation (CDE)’s 2020 reporting, including an overview of administrative drug approvals and fast track…
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its own mRNA vaccine; an update on Hong Kong’s biotech investment ecosystem three year…
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), picks out the key learnings from recent legislation to improve China’s drug regulatory capacity and why it…
The following is an overview from Accestra Consulting* of Part 1 of China’s Center for Drug Evaluation (CDE)’s 2020 reporting, including data on drug approvals for all application types (including…
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, and Sanofi have achieved China growth in…
In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric Bouteiller examine the potential impact of China’s revision to its patent law on the…
In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong Chow has left her role as General Manager for Roche…
The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant Simcere and German biotech Vivoryon in Alzheimer’s; Innovent’s tie-up with Ascentage; Biogen’s USD 125 million…
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene therapy space, as multinationals look…
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta; the Big Pharma losers from the latest round of price cuts for off-patent…
See our Cookie Privacy Policy Here
